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Report of Eight Recent Cases of Locally Advanced Primary
Pulmonary Artery Sarcomas: Failure of Doxorubicin-Based
Chemotherapy
Nicolas Penel, MD, PhD,*† Sophie Taieb, MD,‡ Luc Ceugnart, MD,‡ Eric Dansin, MD,*
Dominique Hoguet, MD,* Luc Vanseymortier, MD,* and Eric Lartigau, MD, PhD§
Background: Case reports of primary pulmonary artery sarcomas
are very rare.
Methods: We described herein eight new cases diagnosed between
December 2000 and December 2004.
Results: There were four men and four women, with median age of
52 years. Presenting symptoms mimicked pulmonary emboli in all
cases. There were six “intimal sarcomas” and two leiomyosarcomas.
In six cases, we observed initial metastasis in lung (six cases), in
bone (two cases), and in brain (two cases), and adrenal gland (one
case). The palliative treatments included surgical desobstruction (six
cases), conformational radiotherapy (four cases), and chemotherapy
(seven cases). Doxorubicin-based regimen failed in seven cases. All
patients died (median survival: 8 months, extremes 5–20 months).
Conclusion: Those eight cases illustrate the high incidence of initial
metastasis and the very poor outcome of primary pulmonary artery
sarcomas despite classic doxorubicin-based chemotherapy.
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artery, Outcome, Doxorubicin.
(J Thorac Oncol. 2008;3: 907–911)
Primary pulmonary artery sarcoma (PPAS) is an excep-tional cancer. Its estimated incidence is about 0.001 to
0.003%.1–3 Data about its clinical outcome are very spare.
Since its first description in 1923, literature data consists in
about 150 cases.1–4 Few years ago, because of the rarity of
this tumor and its nonspecific presenting symptoms, this
diagnosis was usually postmortem. New imaging techniques
(such as transesophageal echocardiography, helicoidal com-
puted tomography [CT], and magnetic resonance imaging
[MRI]) play a key role in diagnosis and preoperative assess-
ment of PPAS. Well-planned large en bloc resection of tumor
is the treatment of choice. Nevertheless, despite surgery, the
prognosis of PPAS is poor, because most of those tumors
develop metastasis. We describe herein the outcome of eight
consecutive locally advanced PPAS.
PATIENTS AND METHODS
The Oscar Lambret Cancer Centre is the comprehen-
sive Cancer Centre of northern France. About 950 adult
patients with soft tissue or visceral sarcoma were treated from
December 2000 to December 2007. Among those 950 pa-
tients, eight presented a case of biopsy-proven PPAS. The
records of those patients were available for review and were
retrospectively analyzed.
RESULTS
There were four men and four women. The median age
at the time of diagnosis was 52 years (range, 47–59). Two
patients had tobacco consumption history. In all cases, pre-
senting symptom mimicked a “pulmonary embolism.” Two
of them experienced paraneoplastic fever (Table 1). In three
cases, MRI suggested diagnosis of PPAS before surgical
exploration. In seven cases, histologic diagnosis was estab-
lished by analysis of specimen obtained by emergency sur-
gical exploration. In one case, diagnosis was obtained by
biopsy of lung metastasis. In six cases, the histologic subtype
was “spindle-cells sarcoma without differentiation” (“intimal
sarcoma”). The two others PPAS were classified as differen-
tiated leiomyosarcoma.
Only one patient (case 1) was free of metastasis at
initial diagnosis.
In six cases, PPAS were associated with concomitant
metastasis: lung metastasis (seven patients), mediastinal
lymph node metastasis (two patients), bone metastasis (two
patients), cerebral metastasis (two patients), and adrenal me-
tastasis (two patients).
Only one patient (case 1) underwent initial complete
resection (resection of trunk of artery pulmonary associated
with total pneumonectomy). Six patients received palliative
surgical desobstruction, followed by radiotherapy (50–54
Grays) in four cases.
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Seven patients received doxorubicin-based chemother-
apy regimen: doxorubicin as single agent in three cases and
an association (doxorubicin-ifosfamid-dacarbazine) in the
four other cases. There were no objective response and no
long-lasting stabilization. The median number of front-line
chemotherapy was four. During the course of the disease, we
had diagnosed brain metastasis in four cases. There was no
major toxicity of chemotherapy (no cardiac failure related to
doxorubicin). All patients died with progressive disease. The
median survival was 8 months (range, 5–20).
TABLE 1. Outcome of Eight Recent Primary Pulmonary Artery Sarcoma
Case Sex Age
Presenting
Symptoms Initial Metastasis Initial Treatment
Metachronous
Metastasis Outcome
1 (August 2003) M 48 PH Absent Large resection Lung (4 mo) Died at 6 Mo
Skin and liver (5 mo)
2 (July 2003) F 53 PH and fever Mediastinal lymph nodes Palliative desobstruction
and radiotherapy
Cerebral (6 mo) Died at 8 mo
Lung Bone (6 mo)
3 (September 2003) F 47 PH Lung (one solitary) Palliative desobstruction Skin and liver (8 mo) Died at 8 mo
4 (October 2002) F 57 PH and bone pain Bone (spine) Palliative desobstruction Died at 5 mo
Cerebral
5 (March 2001) F 52 PH Mediastinal lymph nodes Palliative desobstruction
and radiotherapy
Cerebral (19 mo) Died at 20 mo
Lung and pleura
6 (September 2001) M 59 PH, fever, and bone
pain
Bone Palliative desobstruction
and radiotherapy
Spleen (4 mo) Died at 5 mo
Adrenal Liver (4 mo)
Cerebral
Lung
7 (December 2004) M 52 PH Lung Palliative chemotherapy Adrenal (4 mo) Died at 8 mo
Liver (4 mo)
8 (March 2007) M 52 PH Lung Palliative desobstruction,
radiotherapy, and
chemotherapy
Brain (8 mo) Died at 13 mo
Diaphragm (8 mo)
Bone (8 mo)
PH, pulmonary hypertension.
TABLE 2. Chemotherapy Result
Case Sex Age
Histological
Diagnosis
First-line
Chemotherapy
Number of
Cycles Results Following Treatment
2 (July 2003) F 53 Intimal sarcoma MAID regimen (1) 6 Apparition of cerebral and bone
metastasis
Second-line chemotherapy
(Ifosfamide 9 g/m2;) with
progressive diseaseStabilization of lung metastasis (2)
3 (September 2003) F 47 Intimal sarcoma MAID regimen (1) 6 Stabilization of lung metastasis and
regression of primitive tumor
Best supportive care
Apparition of skin and liver
metastasis
4 (October 2002) F 57 Differentiated
leiomyosarcoma
Doxorubicin alone:
75 mg/m2;/3 wk
3 Progression of lung metastasis and
primitive tumor
Best supportive care
5 (March 2001) F 52 Differentiated
leiomyosarcoma
Doxorubicin alone:
75 mg/m2;/3 wk
3 Progression of lung metastasis (2) Second-line chemotherapy
(Ifosfamide 3 g/m2;)
with a long stabilization
(10 mo)
6 (September 2001) M 59 Intimal sarcoma MAID regimen (1) 4 Apparition of spleen and liver
metastasis
Best supportive care
Stabilization of cerebral, lung and
adrenal metastasis (2)
7 (December 2004) M 52 Intimal sarcoma MAID regimen (1) 4 Apparition of liver and adrenal
metastasis
Best supportive care
Stabilization of lung metastases and
primary tumor
8 (March 2007) M 52 Intimal sarcoma Doxorubicin alone:
75 mg/m2;/3 wk
4 Apparition of brain and
diaphragmatic metastases (2)
Best supportive care
(1) MAID, doxorubicin 20 mg/m2; (J1–J3); ifosfamide 2 g/m2; (J1–J3); dacarbazine 300 mg/m2; (J1–J3); and granulocyte growth factor, day 1  day 21.
(2) Primary tumor response is not assessable because of previous radiotherapy.
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DISCUSSION
Presenting Signs
PPAS is an extremely rare cancer. Most of patients
present between the age of 45 and 55 years, with women
outnumbering men by a ratio of 2:1.5 Few years ago, the
diagnosis of PPAS was rarely established because the symp-
toms were insidious and nonspecific. Indeed, pulmonary
embolism is the most common initial clinical diagnosis in a
large series. Nevertheless, atypical features are present, such
lack of predisposing factors for thromboembolism, persis-
tence, and recurrence of symptoms despite adequate antico-
agulation, and unilateral of massive perfusion defect.6–8 Con-
sequently, many patients were treated for weeks or months
with anticoagulation before a tissue diagnosis was rendered
(Figures 1, 2). The failure of anticoagulation precipitates
modern imaging exploration and most of definitive diagnosis
comes after surgical exploration for presumed thromboem-
bolic disease with pathologic examination of the resected
specimen. This incorrect diagnosis can delay proper therapy.
New noninvasive techniques such as transesophageal
echocardiography, helicoidal CT, and MRI are more sensitive
for the detection of cardiac tumors. MRI easily demonstrates
the intravascular mass of PPAS and delineates intraluminal
FIGURE 1. Woman, 52-year old (case 5). Helical CT with
contrast: unilateral of massive perfusion defect in right pul-
monary artery seems pulmonary embolism.
FIGURE 2. A, MRI performed 4
weeks later because of failure of
anticoagulation. T1-weighted im-
ages show intermediate heteroge-
neous signal intensity in right pul-
monary artery with irregular
margins and superior vena cava
infiltration (arrow). Right pleural
effusion appears (arrow head). B,
After contrast administration: the
lesion seems heterogeneous with
large central necrosis. Signal of pe-
ripheral zone is enhanced by con-
trast.
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spread in the pulmonary arteries. In addition, MRI is well
suited for the anatomic or functional demonstration of tumor
extension to the pulmonary valve and involvement to the
pericardium.9 Although distinguishing an intraluminal-filling
defect caused by thrombus from one caused by PPAS could
be very difficult, contrast enhancements in an intraluminal
mass on MRI suggest PPAS.9,10 Extension of the tumor
beyond the vessel margins clearly confirms a neoplastic
etiology.11 In a literature review in 1990, Kruger et al. found
93 cases of PPAS, with 60% diagnosed postmortem.12 Cox et
al., in 1997 found 42 additional cases with 90% diagnosed
antemortem.4 The major factor in improved diagnosis seems
to be use of MRI, where enhancement of with gadolinium
helps differentiate tumor from thrombus. Those techniques
aid preoperative assessment. Despite these favorable imaging
characteristics, distinction of PPAS from embolism has re-
mained difficult, necessitating cytologic or histologic analy-
sis. Nowadays, diagnosis of PPAS is made preoperatively in
about 50% of cases.11
Histologic Diagnosis
Transbronchial lung biopsy can be helpful, but it carries
the risk of bleeding in patients with pulmonary hypertension.
Another technique of diagnosis is pulmonary catheter sam-
pling; however, this technique has some technical difficulties
and requires an experimented pathologist.13 In most cases,
diagnosis is obtained by analysis of resected sampling. Most
of these tumors arise from primitive intimal cells. They are
most conveniently grouped as “intimal sarcomas,” because
they show no discernible differentiation, or minimal fibro-
blastic, or smooth muscle differentiation. Differentiated soft
tissue sarcomas are observed, such as osteosarcoma, leiomy-
osarcoma, angiosarcoma, or myxoid liposarcoma.14 Main
differential diagnoses are Takayashu arteritis, giant cell ar-
teritis, fibrosing mediastinis, and extension of lung cancers or
mediastinal tumors.14
Initial Extension
PPAS most often arise in the pulmonary trunk and may
form a nodular intraluminal mass, or they may spread along
the intimal surface. Retrograde spread can involve the pul-
monary valve and right ventricle, whereas anterograde spread
is along the pulmonary artery branches into the lung. Direct
transmural spread of tumor occurs in approximately 50% of
cases. Invasion of structures adjacent to the heart by tumor
can causes hemoptysis or dysphonia. Initial pulmonary are
present in 40% of the patients. But, emboli from these tumors
to the lungs or peripheral arteries may mimics embolic
disease. In our experience, seven tumors arise from pulmo-
nary trunk and one from left pulmonary artery (case 1). In
four cases, we observed large transmural extension associated
with hemoptysis. Only one patient was free of metastasis at
diagnosis. Seven patients had lung metastases (one solitary
metastasis in only one case), and four patients had extratho-
racic metastases. Excluding bone metastases, those extratho-
racic metastases were asymptomatic and were discovered
during systematic assessment.
Treatment
Initial complete resection is often impossible. Complete
resection using resection with graft and pneumonectomy has
been reported in few cases, with long remission. Neverthe-
less, resection is often incomplete because the advancement
of the tumors. In most cases, the aim of the surgical procedure
is to relieve the symptoms of cardiac chamber, valve, or
major blood vessel obstruction. There is no evidence for
adjuvant radiotherapy or chemotherapy, but patients with
long survival had multimodal approach.15,16 In our experi-
ence, only one patient had complete resection without adju-
vant treatment. In that case, metachronous metastases were
observed at 4 months. In six cases, the surgical procedure was
palliative with desobstruction. In four cases, conformational
radiotherapy had very good palliation on pulmonary hyper-
tension and hemoptysis related to bronchus involvement.
Seven patients received chemotherapy with doxorubicin,
without efficacy. We had observed long-lasting stabilization
with ifosfamide (case 5). Further chemotherapy combination
should be evaluated in this indication.
Outcome and Survival
In our experience, all patients had developed metasta-
ses. All patients presented lung metastases. The occurrence of
brain metastases is high in comparison with other location of
soft tissue sarcoma. Sarcomas of all types accounted for less
than 3% of brain metastases in an autopsy series reported in
1964.17 The median survival of PPAS is classically 8 months.
The mean survival after diagnosis without treatment is short
with only 1.5 months, but can be considerably extended by
total excision of the tumor. Moffat et al. reported on survival
rates ranging from a few weeks up to 3.5 years.18,19 Recent
data indicate a survival of even 10 years or more after
complete surgical resection, so that, the operative procedure
should be favored whenever possible.20,21
CONCLUSION
PPAS is rare. Presenting symptoms are nonspecific.
MRI allows obtaining precocious diagnosis.4 We observe that
initial systemic extension is very frequent. Recent data indi-
cate that long survival is obtained by large complete resection
in a multimodal approach. Nevertheless, we observed that
initial or rapid metachronous metastasis is frequent, particu-
larly in brain. In those cases, classic doxorubicin-based reg-
imen seems ineffective.
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